Share >  
Share
Share on Tumblr

Hexal

News »

   latest by relevance
See 20% growth despite Re rise: Dr Reddy's
Jun 25, 2007 at 11:00
GV Prasad, Vice Chairman and CEO at Dr Reddy's Laboratories has said that a significant part of their business comes from the US but the rising Rupee is expected to hit margins.
Matrix-Mylan deal demystified: An analysis
Aug 28, 2006 at 15:53
Mylan has said that it will pick up more than a 71% stake in Matrix Labs in a deal, which values Matrix at just over a billion dollars. Analysts say that right now, Matrix is valued quite well and in terms of operational synergies, this is the best fit that can happen to any company.
What's in store for generics? ABN AMRO has the answers
Feb 17, 2006 at 12:16
Giridhar Iyengar at ABN AMRO believes that the next five years will prove to be the best for the pharma generics space. He adds that Indian pharma companies prefer the M&A route in Europe.
Dr Reddy's: How is it placed post Betapharm deal?
Feb 16, 2006 at 11:11
The pharma space is abuzz again as Dr Reddy's has bagged private equity firm 3i's 80% stake in Betapharm for 480 million Euro, leaving competitors like Ranbaxy behind. Experts believe that this will of course augur well for the stock, as well as boost the company in India and Europe.
Dr Reddy's wins race for Betapharm for 480 mn Euro
Feb 16, 2006 at 09:00
The battle for Germany's fourth largest generic firm Betapharm has finally come to a close and it's fairly sure now that Dr Reddy's has clinched it. Dr Reddy's will pay 480 million Euro to acquire Betapharm.
3i Group PLC considering Betapharm sale
Nov 29, 2005 at 13:33
Private equity company, 3i Group PLC is considering selling German generic drug manufacturer, Betapharm. However, it is not into exclusive talks for the sale as yet.

Videos »
See 20% growth despite Re rise: Dr Reddy's
Matrix-Mylan deal demystified: An analysis
more »

Photos »

  /  
Related News »
RNCOS Releases a New Report - G-CSF Biosimilars Market Forecast to 2015
The competitive landscape talks about the activities of companies like Sandoz, Hospira and Hexal, and their key G-CSF products. Overall, the extensive research presents an objective outlook of the global G-CSF biosimilars market to clients.
May 18, 2012 at 03:26 | Source: SBWire

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window